Search Results - "OGASAWARA Ken" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Serum amyloid A and LDL complex

Serum amyloid A and LDL complex

by Mashiba, Shinichi, Uchida, Kazuo, Ogasawara, Ken
Published in Nihon rinshō (01.11.2004)

Get more information

Journal Article

$Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT$

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

by Bachier, Carlos R., Palomba, Maria Lia, Abramson, Jeremy S., Andreadis, Charalambos, Sehgal, Alison R., Godwin, John, Hildebrandt, Gerhard C., Siddiqi, Tanya, Stevens, Don, Farazi, Thalia, Kostic, Ana, Trede, Nikolaus S., Wang, Lei, Lymp, James, Thelen, Tennille, Ogasawara, Ken, Maloney, David G.
Published in Blood (13.11.2019)

Get full text

Journal Article

How should we treat for ischemic heart disease in dialysis patients: PCI or CABG?

How should we treat for ischemic heart disease in dialysis patients: PCI or CABG?

by Nakagawa, Yuya, Oikawa, Yuji, Yajima, Junji, Funada, Ryuichi, Matsuno, Shunsuke, Inaba, Toshiro, Nakamura, Michinari, Ogasawara, Ken, Kirigaya, Hajime, Nagashima, Kazuyuki, Sawada, Jun, Aizawa, Tadanori
Published in Shinzo (2009)

Get full text

Journal Article

$Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001$

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

by Palomba, Maria Lia, Gordon, Leo I., Siddiqi, Tanya, Abramson, Jeremy S., Kamdar, Manali, Lunning, Matthew A., Maloney, David G., Andreadis, Charalambos, Arnason, Jon E., Ghosh, Nilanjan, Mehta, Amitkumar, Solomon, Scott R., Farazi, Thalia, Garcia, Jacob, Dehner, Christine, Ogasawara, Ken, Gao, Jie, Wang, Michael
Published in Blood (05.11.2020)

Get full text

Journal Article

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

by Zeidan, Amer M., Boss, Isaac, Beach, C.L., Copeland, Wilbert B., Thompson, Ethan, Fox, Brian A., Hasle, Vanessa E., Ogasawara, Ken, Cavenagh, James, Silverman, Lewis R., Voso, Maria Teresa, Hellmann, Andrzej, Tormo, Mar, O'Connor, Tim, Previtali, Alessandro, Rose, Shelonitda, Garcia-Manero, Guillermo
Published in Blood advances (12.04.2022)

Get full text

Journal Article

Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors

Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors

by Ogasawara, Ken, Xu, Christine, Yin, Jian, Darpo, Borje, Carayannopoulos, Leon, Xue, Hongqi, Palmisano, Maria, Krishna, Gopal
Published in Clinical pharmacology in drug development (01.04.2021)

Get full text

Journal Article

POSTER: MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

POSTER: MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

by Palomba, M. Lia, Siddiqi, Tanya, Gordon, Leo I., Kamdar, Manali, Lunning, Matthew, Hirayama, Alexandre V., Abramson, Jeremy S., Arnason, Jon, Ghosh, Nilanjan, Mehta, Amitkumar, Andreadis, Charalambos, Solomon, Scott R., Kostic, Ana, Dehner, Christine, Espinola, Ricardo, Peng, Lily, Ogasawara, Ken, Chattin, Amy, Wang, Michael
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)

Get full text

Journal Article

$POSTER: CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)$

POSTER: CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

by Linhares, Yuliya, Freytes, Cesar, Cherry, Mohamad, Bachier, Carlos, Maris, Michael, Hoda, Daanish, Varela, Juan C., Bellomo, Courtney, Cross, Scott, Essell, James, Fanning, Suzanne, Terebelo, Howard, Yimer, Habte, Courtright, Jay, Sharman, Jeff P., Kostic, Ana, Vedal, Min, Ogasawara, Ken, Avilion, Ariel, Espinola, Ricardo, Yuan, Brenda, Mattar, Bassam
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)

Get full text

Journal Article

MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

by Palomba, M. Lia, Siddiqi, Tanya, Gordon, Leo I., Kamdar, Manali, Lunning, Matthew, Hirayama, Alexandre V., Abramson, Jeremy S., Arnason, Jon, Ghosh, Nilanjan, Mehta, Amitkumar, Andreadis, Charalambos, Solomon, Scott R., Kostic, Ana, Dehner, Christine, Espinola, Ricardo, Peng, Lily, Ogasawara, Ken, Chattin, Amy, Wang, Michael
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)

Get full text

Journal Article

$CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)$

CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

by Linhares, Yuliya, Freytes, Cesar, Cherry, Mohamad, Bachier, Carlos, Maris, Michael, Hoda, Daanish, Varela, Juan C., Bellomo, Courtney, Cross, Scott, Essell, James, Fanning, Suzanne, Terebelo, Howard, Yimer, Habte, Courtright, Jay, Sharman, Jeff P., Kostic, Ana, Vedal, Min, Ogasawara, Ken, Avilion, Ariel, Espinola, Ricardo, Yuan, Brenda, Mattar, Bassam
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)

Get full text

Journal Article

FABRIC-LIKE SENSOR AND FABRIC-LIKE SENSOR DEVICE

FABRIC-LIKE SENSOR AND FABRIC-LIKE SENSOR DEVICE

by MIYAZAKI Ken, MURAO Masahiro, OGASAWARA Ken, SHIMIZU Satoshi, NAKAJIMA Manabu, SASAKI Masaaki
Year of Publication 01.09.2022

Get full text

Patent

Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus

Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus

by Ionita, Ileana A, Ogasawara, Ken, Gohh, Reginald Y, Akhlaghi, Fatemeh
Published in Therapeutic drug monitoring (01.08.2014)

Get more information

Journal Article

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

by Abramson, Jeremy S, Solomon, Scott R, Arnason, Jon, Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, Kamdar, Manali
Published in Future oncology (London, England) (2024)

Get full text

Journal Article

OUTREACH: Phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

OUTREACH: Phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

by Linhares, Yuliya, Freytes, Cesar O, Cherry, Mohamad, Bachier, Carlos, Maris, Michael B, Hoda, Daanish, Varela, Juan Carlos, Bellomo, Courtney, Cross, Scott, Essell, James H, Fanning, Suzanne, Terebelo, Howard, Yimer, Habte A, Courtright, Jay, Sharman, Jeff P, Kostic, Ana, Vedal, Min, Ogasawara, Ken, Avilion, Ariel, Espinola, Ricardo, Yuan, Brenda, Mattar, Bassam
Published in Blood advances (30.09.2024)

Get full text

Journal Article

Lisocabtagene Maraleucel (liso-cel) As Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplantation (HSCT): Final Analysis of the Phase 2 PILOT Study

Lisocabtagene Maraleucel (liso-cel) As Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplantation (HSCT): Final Analysis of the Phase 2 PILOT Study

by Hoda, Daanish, Sehgal, Alison, Riedell, Peter A., Ghosh, Nilanjan, Hamadani, Mehdi, Hildebrandt, Gerhard C, Godwin, John E., Reagan, Patrick M., Wagner-Johnston, Nina, Essell, James, Nath, Rajneesh, Solomon, Scott R., Champion, Rebecca, Licitra, Edward, Fanning, Suzanne, Gupta, Neel K., Chow, Victor A., Yuan, Brenda, Yang, Zhi, Ogasawara, Ken, Thorpe, Jerill, Gordon, Leo I.
Published in Transplantation and cellular therapy (01.02.2024)

Get full text

Journal Article

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

by Palomba, M. Lia, Siddiqi, Tanya, Gordon, Leo I., Kamdar, Manali, Lunning, Matthew, Hirayama, Alexandre V, Abramson, Jeremy S., Arnason, Jon, Ghosh, Nilanjan, Mehta, Amitkumar, Andreadis, Charalambos, Solomon, Scott R., Kostic, Ana, Singh, Ashvin, Espinola, Ricardo, Peng, Lily, Ogasawara, Ken, Chattin, Amy, Wang, Michael
Published in Transplantation and cellular therapy (01.02.2024)

Get full text

Journal Article

Increased level of advanced oxidation protein products in patients with coronary artery disease

Increased level of advanced oxidation protein products in patients with coronary artery disease

by Kaneda, Hideaki, Taguchi, Junichi, Ogasawara, Ken, Aizawa, Tadanori, Ohno, Minoru
Published in Atherosclerosis (01.05.2002)

Get full text

Journal Article

Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016

Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016

by Alexander, G. Caleb, Ogasawara, Ken, Wiegand, Dana, Lin, Dora, Breder, Christopher D.
Published in Therapeutic innovation & regulatory science (01.11.2019)

Get full text

Journal Article

Hepatocyte nuclear factor-4α regulates the human organic anion transporter 1 gene in the kidney

Hepatocyte nuclear factor-4α regulates the human organic anion transporter 1 gene in the kidney

by Ogasawara, Ken, Terada, Tomohiro, Asaka, Jun-ichi, Katsura, Toshiya, Inui, Ken-ichi
Published in American journal of physiology. Renal physiology (01.06.2007)

Get full text

Journal Article

$Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product$

Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product

by Solomon, Scott R., Mehta, Amitkumar, Abramson, Jeremy S., Siddiqi, Tanya, Lunning, Matthew, Maloney, David G., Kamdar, Manali, Kostic, Ana, Kim, Yeonhee, Ogasawara, Ken, Palomba, M. Lia
Published in Transplantation and cellular therapy (01.03.2021)

Get full text

Journal Article

[1]
Prev
1
2
3
4
5
6
7
8
9
10
Next
[10]